| Document |
Document Title |
|
JP4001542B2 |
The present invention relates to novel to N-adamantylalkyl benzylamide derivatives of formmula I and to process for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use ...
|
|
JP2007529496A |
Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formul...
|
|
JP2007529280A |
Dry powders containing bioresorbable hyaluraonic acid (“HA”) are applied directly to a desired location in a patient wound to reduce adhesions, without first forming a hydrated gel. HA includes hyaluronic acid that has been modified,...
|
|
JP2007529418A |
Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a subject in need thereof comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor ...
|
|
JP3997056B2 |
The present invention relates to a nuclear transport agent, to a gene transfer system comprising said nuclear transport agent, to a method for transporting DNA into the nucleus of eukaryotic cells using said nuclear transport agent and t...
|
|
JP2007269646A |
To provide a method for effectively modifying only the outer surface of a liposome without causing the leakage of the included drug from the liposome or the degradation of the drug while supporting the surface-modifying agent to the lipo...
|
|
JP3994051B2 |
The present invention is a series of compounds that are derivatives of 1-sulfonyl-pyrrolidine and that demonstrate affinity towards metabotropic glutamate receptors. The invention further relates to medicaments containing these compounds...
|
|
JP3993647B2 |
Use of beta-naphthoquinone derivatives of formula (I): in which R is an -NH-CO-NH2 or -NH-CO-CH3 group or a hydroxyl, and their salts, for the manufacture of a medicinal product enabling the proliferation of endothelial cells to be accel...
|
|
JP2007262057A |
To provide new isomer and 42-epimer of rapamycin analog having different polarity of whole compounds capable of exerting different stability and solubility characteristics in compositions. Isomers and 42-epimers of rapamycin alkyl ether ...
|
|
JP2007260393A |
To provide a blood substitute which has capability of transporting and moving a sufficient quantity of oxygen to a tissue under a circumferential condition and good retention time in the blood vessel. In an oxygen protective film double ...
|
|
JPWO2005072753A1 |
An object of the present invention is to provide highly active platelet-rich plasma easily and inexpensively. The whole blood obtained by collecting blood is selectively precipitated by coagulating and precipitating erythrocytes regardle...
|
|
JP2007262074A |
To provide a new human CC-chemokine receptor, to provide an antibody against the receptor or an antigenic bonded fragment thereof and to provide a pharmaceutical composition comprising the same. A mammalian (e.g. human) CCR2 [CC-chemokin...
|
|
JP2007527711A |
The present invention features compositions (e.g., nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulati...
|
|
JP2007527704A |
The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polyn...
|
|
JP2007527520A |
Methods are disclosed for providing a library of composite or novel composition samples on a support. The method involves depositing one or more components as concentration gradients on the surface of the support. The concentration gradi...
|
|
JP3978135B2 |
Substituted anthranilic acids of the formula Itheir use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker.
|
|
JP2007526239A |
Described herein are composites that inhibit or reduce adhesion between two or more tissues. Also described herein are methods of using the composites.
|
|
JP2007231015A |
To provide rapamycin derivatives having potentially enhanced stability, different solubility profiles from rapamycin in liquid formulations and improved tissue distribution characteristics. Isomers at the 15-C positions of rapamycin and ...
|
|
JP3975318B2 |
|
|
JP2007525425A |
The present invention relates to novel derivatives of human glucagon-like peptide-2 (GLP-2) peptides, which have a protracted profile of action, as well as pharmaceutical compositions, uses and methods of treatment.
|
|
JP2007525193A |
Methods for accumulating, recruiting and retrieving stem cells from a body cavity space of an adult mammal are disclosed, in addition to compositions and cells in accordance with the present invention. In accordance with another aspect o...
|
|
JP2007525485A |
This invention relates to combination therapies involving radiotherapy and chemotherapy. In particular the invention relates to the use of isoflavones or analogues thereof in combination with radiotherapy or chemotherapy in the treatment...
|
|
JP2007524591A |
The present invention provides compositions and methods for specifically inhibiting host immune responses against expression vectors and target cells transfected with such vectors. In particular, methods of specifically inhibiting the hu...
|
|
JP2007524655A |
Formulations comprising one or more epothilones together with a pharmaceutically acceptable carrier.
|
|
JP2007217699A |
To provide a method for preparing biocompatible crosslinked polymers. Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water-solu...
|
|
JP2007524579A |
The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals, and to pharmaceutical compositions useful therefor com...
|
|
JP2007524566A |
The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The inve...
|
|
JP3967679B2 |
The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R<1> is a hydrogen atom or an optionally substituted lower alkyl group; R<2> is a di(lower alkyl)amino group,...
|
|
JP2007211022A |
To provide the treatment of immune response-related diseases and inhibition of unwanted immune response with an aglycosyl anti-CD154 antibody or an antibody derivative thereof. The aglycosyl anti-CD154 antibody or the antibody derivative...
|
|
JP2007523876A |
This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia.
|
|
JP2007521803A |
The invention relates to the fields of biology, genetics and medicine. The invention describes methods and compositions enabling (1) the identification of suppressor T cells or lymphocytes (Ts) or the precursors thereof (pTs) for diagnos...
|
|
JP3953511B2 |
Disclosed and claimed are methods for the isolation and use of stem cell inhibiting factors for regulating the abnormal stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed...
|
|
JP2007190399A |
To provide an instantly usable absorptive composition useful for tissue gluing, tissue sealing, and hemostasis avoiding danger of allergy, hazardous virus contamination, BSE, etc. The present invention relates to a solid composition comp...
|
|
JP2007520538A |
Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.
|
|
JP2007182407A |
To provide a sustained-release hydrogel preparation capable of regulating the elution of galectin-1 or a galectin-1 derivative in a living body of a mammal.The sustained-release hydrogel preparation contains a cationic gelatin hydrogel a...
|
|
JP2007176809A |
To provide a heterocyclic ring-substituted amide derivative having an excellent inhibitory action on acyl-CoA:cholesterol acyltransferase, a method for preparing the same, and the use thereof.The pharmaceutical composition comprises a co...
|
|
JP2007504273T5 |
|
|
JP2007516747A |
Biodegradable, compression resistant microparticles adapted for injection through a catheter system, such as is useful for selective embolization procedures. The microparticles can optimally be neutrally buoyant relative to a target bodi...
|
|
JP3938689B2 |
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4 is -COOH or tetrazolyl; A, B...
|
|
JP2007516176A |
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical...
|
|
JP2007516434A |
Disclosed herein are compounds that selectively activate the FPRL1 receptor. Further disclosed are methods of alleviating inflammatory responses by regulating key steps in leukocyte trafficking and preventing neutrophil-mediated tissue d...
|
|
JP2007145765A |
To obtain a composition for an ophthalmic operation, which simultaneously satisfies three requirements of anterior chamber depth formation ability, intraocular retention ability and removal easiness for protecting a corneal endothelium w...
|
|
JP2007143674A |
To provide a tissue body which can make the thickness of the tissue body being formed drastically larger, and in addition, can newly generate a large amount of blood vessels including capillary vessels by maturing.An artificial object, w...
|
|
JP2007137771A |
To provide an inflammatory disease therapeutic agent containing siRNA against midkine as an active ingredient, and a method of treating or preventing inflammatory diseases comprising a step of administering siRNA against midkine to a per...
|
|
JP2007514648A |
The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.
|
|
JP3924028B2 |
To obtain a sulfonimidamide useful as a medicine for treating arrhythmia, suitable for intravenous dosage, more improved in water solubility than a well-known compound. This compound is shown by formula I (at least one of R(1), R(2) and ...
|
|
JPWO2005047286A1 |
In the present invention, the general formula (I) (wherein D and G represent a cyclic group which may have a substituent or an alkyl group which may have a substituent, W and Y are represented by W and Y. Representing a spacer having 1 t...
|
|
JP2007131644A |
To provide a composition for rapidly and simply carrying out the protuberance of epithelium, facilitating the injection of a solution through a thin catheter and capable of keeping the protuberance of the epithelium high.The composition ...
|
|
JP2007131635A |
To provide a method for treating a mammal by a small peptide exhibiting antifibrotic activities; and to provide a method for obstructing, preventing and more effectively reducing the fibrosis in the mammal by the method.An antifibrotic e...
|
|
JP2007513962A |
Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically ...
|
